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ABSTRACT
The process of breast tumor metastasis has been examined to a great extent in
recent years, but connecting specific protein-protein interactions to respective metastatic
events remains challenging. The primary cause of death in patients with breast cancer is
not from the primary tumor itself but rather from tumor metastases, which cause over
90% of all mortalities. In order for tumor cells to metastasize, they must undergo a
phenotypic change known as the epithelial-mesenchymal transition (EMT). An EMT
allows for the intravasation of tumor cells into nearby blood vessels or lymphatic
channels. Once the primary tumor cells are within the network of vessels, they undergo a
homing process to specific organs within the body. For breast cancer, secondary
metastatic locations include the liver, brain, lung, and bone. It is known that signaling by
proteins called cytokines influences breast tumor cells to adopt a more metastatic and
aggressive phenotype. Cytokine signaling often changes protein functioning in the
surrounding tumor environment and can lead to increased vasculature, which provides
nutrients to a growing tumor, or phenotypic changes to individual cells on the invasive
edge of a proliferating tumor. Transmembrane proteins, such as cluster of differentiation
44 (CD44), contribute to cell migration, cell detachment, and cellular docking during
metastasis. The upregulation of CD44 expression by cytokine signaling is observed in
less aggressive tumor cells, while more aggressive tumor cells constitutively express high
basal levels of CD44. Both EMT and CD44 induced by cytokines are involved in
metastasis during specifically timed events in the metastatic cascade.
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CHAPTER ONE: INTRODUCTION
Breast Cancer

According to the American Cancer Society, roughly 252,710 new cases of
invasive breast cancer will be diagnosed in women in the United States in 2017 (1). The
American Cancer Society projects mortality from the disease will reach roughly 40,610
women during this year alone (1), and the risk of a woman developing breast cancer at
some point in her life is currently 1 in 8 according to breastcancer.org. The epithelial
cells lining lactiferous ducts are the most common location for the formation of breast
cancer and lead to invasive ductal carcinoma (IDC). IDC occurs in ~80% of breast cancer
cases (2), as compared to invasive lobular carcinoma that makes up roughly 10% of
breast cancer cases and originates from glandular tissue (3). Inflammatory breast cancer
and a few other rare types make up the remaining 10%. IDC develops through a series of
steps. Normal breast epithelium progresses to atypical breast hyperplasia that changes to
ductal carcinoma in situ, which may be followed by malignant IDC. In some cases ,
metastatic disease will develop (4).
Breast Cancer Subtypes
Breast cancer cannot be treated as a single, straightforward disease; instead each
individual diagnosis is categorized into a subtype based on the origination of the tumor
(ductal versus lobular) and the hormone and growth factor receptors present on the tumor
cells. It is the specific subtype of breast cancer that dictates the use of certain therapeutic
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interventions as well as the prognosis for the patient. Patients with luminal A, luminal B,
human epidermal growth factor receptor 2 (HER2), and triple negative breast cancer
(TNBC) are four of the most common subtypes of breast tumors (5). Luminal A breast
cancer presents with low Ki-67 expression and is estrogen receptor-positive (ER+),
progesterone receptor-positive (PR+) or negative (PR-), and HER2 negative. Luminal A
is considered a highly treatable subtype (6). It also is the most common subtype, resulting
in 150,000 cases each year (7). Luminal B expresses lower levels of hormone receptors
and higher levels of proliferation markers compared to luminal A (8). The subtype HER2
is HER2+ and is found in roughly 20% of breast cancers (9). The final subtype is TNBC
(ER- PR- HER2-), which does not possess any of the above mentioned receptors and is
considered one of the most difficult subtypes to treat based on the limited amount of
therapeutic intervention possible due to the absence of all three receptors (10).
Metastatic Breast Cancer
It is widely known that breast cancer is easily treatable if caught in early stages
and if the tumor cells are ER+ (11). Most breast cancer is lethal as a result of local
invasion and metastasis of tumor cells from the primary tumor to other tissues such as the
lung, bone, brain and liver (12, 13). Surgery and other treatments can be used to remove
or inhibit the primary breast tumor. But there is a risk of not eliminating or destroying
every cancer cell within the tumor, which can lead to recurrence and metastasis (14–16).
The stepwise events involved in metastasis are commonly referred to as the metastatic
cascade (Fig. 1). These events happen in sequential order and begin as soon as the
primary tumor cells undergo changes that allow for a more aggressive nature. Primary
tumor cells lose cell-cell adhesion proteins allowing for individual cellular migration and
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invasion towards the vasculature. This is followed by intravasation of the tumor cell into
the fluid network of the bloodstream (17). Once in the bloodstream, tumor cells circulate,
dock, and undergo extravasation. Finally, the cells colonize a secondary site, where they
establish a metastatic tumor at a distal location.
A crucial step in the metastatic cascade is the epithelial-mesenchymal transition
(EMT), a key event where a cell undergoes a phenotypic change from an epithelial to a
more aggressive mesenchymal phenotype. This process is absolutely necessary during
development, wound healing, and also tumor progression. Epithelial markers and
mesenchymal markers fluctuate during the transition. Two important epithelial markers
are the proteins E-cadherin and -catenin, which participate in cell-cell adhesion (18, 19).
Without EMT, cuboidal epithelial cells would not be able to become mobile, which is
necessary for tumor cells to invade and metastasize. Cytokine signaling influences EMT
through the activation of transcription factors that repress epithelial markers.
Oncostatin M (OSM)
Oncostatin M (OSM) is a pleiotropic, interleukin-6 (IL-6) family cytokine, which
is important in inflammation and necessary for immune function. As an inflammatory
cytokine, OSM can accumulate in the tumor microenvironment (TME) (20). Tumor cells,
as well as monocytes, macrophages, and neutrophils, secrete OSM (21). OSM activates
the JAK/STAT, MAPK, and PI3K/AKT pathways (22, 23) via binding its receptors,
OSM receptor (OSMR) or leukemia inhibitory factor receptor (LIFR). OSMR and LIFR
are heterodimers that each consist of a common gp130 subunit dimerized with either
OSMRor LIFRβ (24). Our studies, as well as other published data, have shown that
OSM inhibits proliferation of breast cancer cells while increasing metastatic capacity
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Patient biopsy studies have demonstrated that increased OSMRβ expression on breast
tumor cells is also associated with tumor progression (25), suggesting tumor cells have
increased signaling from the OSM accumulated in the TME. As an inflammatory
cytokine, OSM plays a role in other cancers besides breast cancer, such as prostate,
cervical, and ovarian carcinoma, where OSM promotes tumor proliferation (26–29).
OSM also plays a role in hepatic and endometrial carcinoma, as an inducer of a more
aggressive metastatic phenotype while decreasing proliferation of tumor cells (30, 31).
Recent work has shown that OSM is directly capable of suppressing estrogen
receptor (ER) expression, which decreases the chance that hormone-blocking therapeutics
will be able to delay tumor progression (32). Cancer-associated adipose tissue is also
capable of increasing breast cancer progression through OSM signaling and the
JAK/STAT3 pathway (33). OSM is not just a molecule involved in cancer progression, as
it can be found to have positive functions in addition to those associated with
inflammation. For example, OSM is also involved in the central nervous system (CNS)
acting as a neuroprotective cytokine during excitotoxic injury in vitro (34). Overall, OSM
signaling events have varying outcomes during inflammation, as well as across different
cancers.
After its initial discovery, OSM was thought to be a potential therapeutic for the
treatment of breast cancer patients because of the inhibitory effects on proliferating breast
tumor cells. As more studies were published, it was discovered that OSM was not only
capable of inhibiting proliferation but was a promoter of metastasis as well (35). Now
breast tumor therapeutics are being developed to target OSM, its receptor, and its
downstream signaling.
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OSM signaling upregulates proteins involved in metastasis. OSM has been shown
to play a role in a number of events in the metastatic cascade such as EMT, cellular
detachment, migration, invasion. OSM induces a metastatic phenotype by encouraging
primary tumor cells to undergo EMT through STAT3 signaling (36). Cellular detachment
is necessary for breast tumor cells to metastasize, and OSM has been shown to be a
strong inducer of this process (37). Breast tumor cells freed from their primary tumor
mass must adopt an invasive characteristic in order to become mobile and enter into the
blood stream (38). Our work suggests that OSM increases the number of circulating
tumor cells and metastasis to lung (manuscript in preparation), and our published work
demonstrates that OSM is needed for osteolytic breast cancer metastasis to bone (35). In
summary, OSM is an important inflammatory cytokine for promoting tumor metastasis.
Cluster of Differentiation 44 (Cd44)
Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein involved in
a variety of cellular processes such as survival and growth, migration and invasion,
lymphocyte activation, and cell adhesion (39, 40). The canonical binding of CD44 to
hyaluronic acid (HA) in the extracellular matrix (ECM) is responsible for CD44’s
downstream effects during tumor progression among many other cellular functions (41).
HA exists in the ECM as a high molecular weight glycosaminoglycan (42). During tumor
progression, high molecular weight HA is cleaved to low molecular weight hyaluronic
acid by hyaluronidase and is capable of binding CD44 and inducing cleavage of the
protein, which in turn promotes cellular migration and reduces the stationary nature of a
cell (43).
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Human CD44 protein contains 19 exons, 9 of which are found in the portion just
outside the cell membrane (Fig. 2) (44). It is within the variable region where CD44 gets
its complexity and specificity for certain types of cancer. The standard form of the
protein (CD44s) contains exons 1-5 and 16-20 with the variable region completely
absent. CD44s alone poses minimal threat in tumor progression relevance and is therefore
not a highly reliable biomarker itself. Identification of which specific CD44 variants are
present is a TME is one way to gain a better understanding of metastatic potential and
general aggressiveness of a primary tumor.
When CD44 alternative splicing occurs, it produces a variety of CD44 variant
proteins (CD44v) (Fig. 3) (45), and it is exons 6-15 that are capable of undergoing
alternative splicing (46–48). Variant exons 6-15 are termed v1, v2, v3, etc. through v10
(49), and a key feature of the exon rearrangements is that there are extensive
combinations. For example, CD44v6 contains only variant exon 6 plus the CD44
standard and is associated with highly aggressive tumors (50). CD44v3-10 contains the
standard exons plus variant exons v3-v10 and is less common than CD44v6 (51). ER+
cell lines possess an epithelial phenotype and contain CD44v8-10, known as CD44E
(CD44 epithelial) (52). Regardless of the combination of exons comprising CD44v,
exons from the CD44s remain present despite alternative splicing.
Whether CD44s or a CD44v protein, the transmembrane CD44 is susceptible to
cleavage by MMPs and -secretase at different locations near the cellular membrane (Fig.
4). During post-MMP cleavage, the extracellular domain (ECD) of CD44 is removed
from the membrane leaving a bound remaining portion of CD44 (53). Subsequent
cleavage by -secretase occurs to this membrane bound portion and releases the
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intracellular domain (ICD), which can then translocate to the nucleus where it
participates in transcriptional activation (54). The processing of CD44 can lead to
changes in outcomes involved in cellular adhesion and migration and ultimately to tumor
invasion and metastasis. (55, 56).
Cancer Stem Cells (CSCs) and Breast Cancer Stem Cells (BCSCs)
The stemness of a tumor cell allows for the loss of regulated cell division when
necessary and the expression of self-renewal genes (57, 58). Cancer stem cells (CSCs),
rapidly proliferating tumor cells, and a host of non-tumor cells make up the
heterogeneous population of a primary tumor (59). Current therapies target rapidly
dividing cells within and around a primary tumor. CSCs are therefore not targeted
because of their non-rapidly proliferating characteristic while in a heterogeneous tumor
population (60).
Cell surface markers used to specifically identify breast cancer stem cells
(BCSCs) are the presence of CD44 (cluster of differentiation 44) and the lack of CD24
(cluster of differentiation 24). This population of BCSCs is known as CD44+/CD24-/low
(61). While little is known regarding BCSCs and metastasis, it is known that
inflammatory cytokines increase the BCSC population from human breast cancer cells
(62). The BCSC population is minor compared to the total tumor cell population, but
BCSCs are speculated to be one of the reasons that recurrence occurs following
treatment.
BCSCs are capable of intravasating into a lymphatic or blood vessel where it
becomes possible for metastasis to take place (63). Following extravasation, it is
speculated that BCSCs are capable of secondary tumor initiation by activating genes
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responsible for proliferation (64). Along with BCSCs, primary tumor cells possess the
ability to survive within the circulation where they are referred to as circulating tumor
cells.
Circulating Tumor Cells (CTCs)
The bloodstream provides a method of transportation for metastatic cells during
breast tumor metastasis. Circulating tumor cells (CTCs) in the blood stream are exposed
to an environment different than that of the primary tumor location. Although the cells
are neither proliferating nor highly active in cell-cell communication, they are able to find
a very specific docking location where extravasation then occurs. A variety of detection
methods for detecting CTCs are available, but therapeutic elimination of CTCs has
remained elusive. However, CTCs can be studied by mimicking in vivo conditions of live
cells in the bloodstream using a BioFlux machine (Fluxion Biosciences, San Francisco,
CA). Flow rates can be controlled to replicate similar shear stress forces that CTCs would
be exposed to in the bloodstream while in transit. Real time video may be recorded to
provide observations of CTC behavior, such as docking and rolling in a fluidic
environment provided insight into the process preceding extravasation.
In Vivo Models of Human Breast Cancer
Murine models are widely used in cancer research because they closely replicate
human cancer characteristics. The athymic nude mouse is commonly used for tumor
studies because it is unable to reject the implantation of human cancer cells (65).
Orthotopic mouse models of human breast cancer involve the injection of tumor into the
mammary fat pad to simulate human breast tumor growth in its natural environment and
subsequent metastasis.
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Patient survival
Although murine models are necessary for gaining insights that lead to novel
therapeutics for the treatment of breast cancer, human data must also be considered.
Cancer transcriptome profiles, available from OncomineTM, may be used to gather data
from patients based on the mRNA expression levels of genes such as OSM, OSMR, and
CD44 expression levels. Survival analyses may be performed to determine the best and
worst potential outcomes based on whether a patient expresses high or low levels of each
gene.
Summary
In summary, the metastatic cascade involves a number of ordered events leading
to secondary tumor formation. OSM signaling contributes to the process by promoting an
EMT in ER+ primary breast tumor cells, which turns a less aggressive cell into a more
aggressive tumor cell. Following EMT, cells become migratory and detach from their
original location in order to intravasate into the blood stream. CTCs and BCSCs travel to
their secondary location where they dock and extravasate before establishing a metastatic
tumor. CD44 contributes to the docking process as the CTCs and BCSCs home to their
secondary location, such as bone, liver, lung and the brain.
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Figure 1.1: Breast tumor cells metastasize through a series of events. Angiogenesis
occurs, which allows for intravasation of invasive and migratory tumor cells into the
vasculature. Cells in circulation eventually create a secondary tumor at a distal
location. (Ma and Weinberg, 2008) (66)
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Figure 1.2: CD44 is composed of exons capable of alternative splicing.
Rearrangement of CD44 exons creates CD44v isoforms that pose larger molecular
weights compared to the standard CD44 (CD44s). (Sen and Yip, 2009) (67)

12

Figure 1.3: CD44 is alternatively spliced while retaining CD44s exons. CD44v6
and CD44v8-10 are commonly present on breast tumor cells. (Xu H. et. al, 2015)
(45)
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Figure 1.4. CD44 is post-translationally cleaved by MMPs. CD44 is cleaved by
MMPs directly adjacent to the cell membrane below the variable region of exons. The
cleavage relieves the extracellular domain (ECD) of being bound to the cellular
membrane. As a second event -secretase cleavage occurs within the membrane
producing an intracellular domain (ICD). (Adapted from Louderbough and
Schroeder, 2011) (68)
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Abstract

Metastasis is the primary cause of mortality in breast cancer patients. Triple
negative breast cancers (TNBC; estrogen receptor-negative, progesterone receptornegative, and HER2-negative) are more aggressive and contribute to higher incidences of
metastasis by possessing characteristics such as increased tumor cell migration and a high
level of the transmembrane protein, cluster of differentiation 44 (CD44). Estrogen
receptor-positive (ER+) breast cancer cells are less aggressive and do not migrate until
undergoing an epithelial-mesenchymal transition (EMT) induced by growth factors or
cytokines. These studies examine the effect of the interleukin-6 (IL-6) cytokine family
member oncostatin M (OSM) on CD44 expression and activity in the metastatic potential
of TNBC and ER+ breast cancer. ER+ T47D and MCF-7 human breast cancer cells
treated with OSM demonstrate increased CD44 expression as well as CD44 cleavage.
Conversely, ER- MDA-MB-231 human breast cancer cells do not show a change in
CD44 expression in the presence of OSM. Knockdown expression of CD44 by shRNA
did not prevent EMT in ER+ cells, but did prevent OSM-promoted metastatic processes
such as cellular detachment and migration. In TNBC cells, CD44 knockdown expression
only reduced tumor cell migration promoted by OSM. In summary, CD44 contributes to
OSM-induced migration and detachment independently of OSM-induced EMT. These
results suggest that regulation of CD44 by OSM contributes to the breast cancer
metastatic cascade.
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Introduction
Metastasis is the primary cause of mortality in cancer patients, leading to over
90% of cancer-related deaths (69). In women with metastatic breast cancer, survival is
poor with a 5-year survival rate of only 26% (1). Continued studies addressing breast
cancer metastasis are necessary if research is to contribute to improved patient outcome.
In order for primary tumor cells to metastasize they must undergo a series of
stepwise events commonly referred to as the metastatic cascade. Tumor cells undergo a
phenotypic change known as an epithelial-mesenchymal transition (EMT) (70–72) and
lose cell-cell adhesion allowing for individual cellular migration and invasion towards the
vasculature. This is followed by intravasation of the tumor cells into the fluid network of
the bloodstream (17). Once the primary breast tumor cells are within the network of
vessels they undergo a homing process to specific organs within the body (73, 74), such
as the bone, lung, liver, and brain before extravasating and colonizing a secondary site
(75–83). The tumor microenvironment (TME) plays a major role in the metastatic
cascade (84), and signaling from cytokines present in the TME lead to tumor cell
phenotypic changes necessary for metastasis to occur (85). Inflammatory cytokines of the
interleukin-6 (IL-6) family such as oncostatin M (OSM) have been shown to be important
in driving tumor invasion and metastasis (37).
OSM is a pleiotropic IL-6-family cytokine, which is important in inflammation
exhibited during breast tumor development (20, 86, 87). Tumor cells including breast
cancer cells, as well as monocytes, macrophages, and neutrophils, secrete OSM (88).
OSM activates the JAK/STAT, MAPK, and PI3K/AKT pathways via binding its
receptors, OSM receptor (OSMR) and leukemia inhibitory factor receptor (LIFR). OSMR
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and LIFR are heterodimers consisting of either OSMRβ or LIFRβ dimerized with a
common gp130 subunit (37, 89, 90). Our previous work and data from the literature have
shown that OSM inhibits proliferation of breast cancer cells, while increasing metastatic
potential (91, 92). OSM has been shown to cause EMT, cell detachment, migration, and
an overall increase in tumor cell aggressiveness. Furthermore, our lab has demonstrated a
direct for OSM in breast cancer metastasis to bone (93).Further investigations are needed
to fully understand the mechanisms by which OSM induces metastatic potential.
Cluster of differentiation 44 (CD44) is a transmembrane glycoprotein involved in
a variety of metastatic events including migration, cell adhesion, and invasion (39, 40,
94). CD44 contains a carboxy-terminal cytoplasmic tail and an amino-terminal region,
which is outside the cell membrane and is folded together by post-translational
glycosylation (95, 96).CD44 is a major receptor for binding hyaluronic acid (HA) in the
extracellular matrix (ECM) (97), and it binds HA by its stem region that is directly above
the surface of the membrane. CD44 can exist as multiple isoforms, which result from
alternative splicing of variant exons (98).
The human CD44 gene contains 19 exons (44), and the standard form of the
protein (CD44s) consists of exons 1-5 and 16-20 with variable region exons (exons 7-15)
completely absent (46–48). CD44s alone poses minimal threat to tumor progression and
is, therefore, not a reliable biomarker. When CD44 alternative splicing occurs, it
produces a variety of CD44 variant proteins (45). Human variant exons 7-15 are termed
v2, v3, v4 through v10 (49), and many CD44 variant (CD44v) isoforms exist (49). It is
within the variable region where CD44 gets it complexity and specificity for certain types
of cancer. For example, CD44v6 contains only variant exon 6 plus the CD44 standard
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and is associated with highly aggressive tumors including breast (50). CD44v3-10
contains the standard exons plus variant exons v3-v10 and is less common than CD44v6
in breast cancer (51). Estrogen receptor-positive (ER+) breast cancer cell lines, which
possess an epithelial phenotype, display CD44v8-10 known as CD44E (52). Regardless
of the combination of exons comprising CD44v, exons from the CD44s remain present
despite alternative splicing.
Whether CD44s or a CD44v protein, the transmembrane CD44 is susceptible to
sequential cleavage by matrix metalloproteinases (MMPs) and -secretase at different
locations near the cellular membrane (53, 99). First, MMPs such as MMP-2 and MMP–9
cleave CD44 just outside the membrane (100).During post-MMP cleavage, the
extracellular domain (ECD) of CD44 is removed from the membrane leaving a bound
remaining portion of CD44 (53). Subsequent cleavage by -secretase occurs to this
membrane bound portion and releases the intracellular domain (ICD), which can then
translocate to the nucleus where it participates in transcriptional activation (54). The
processing of CD44 can lead to changes in outcomes involved in cellular adhesion and
migration and ultimately to tumor invasion and metastasis. (55, 56).
Hyaluronic acid exists in the ECM as a relatively non-active high molecular
weight glycosaminoglycan (42). During tumor progression, high molecular weight HA is
cleaved to low molecular weight hyaluronic acid by hyaluronidase and is capable of
binding CD44 and inducing cleavage of the protein, which in turn promotes cellular
migration and reduces the stationary nature of a cell (43). CD44 has been shown to
interact with ligands other than HA, such as collagens and osteopontin (OPN), and
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depending on which protein CD44 interacts with contributes to differential regulation of
cellular growth and migration (101).
In this study, we demonstrated a connection between OSM-induced breast cancer
metastatic potential and CD44-induced cell migration and detachment. Here, we provided
data showing that OSM both induced the expression of CD44s and CD44 variant proteins
as well as promoted CD44 cleavage. Furthermore, our studies suggested that CD44 may
be necessary for OSM-induced breast tumor cell detachment and migration, both
important events in the metastatic cascade. These findings delineate an important
mechanism by which OSM induces breast cancer metastatic potential.
Materials and Methods
Cell Culture and Cytokine Stimulation
MCF-7 and T47D ER+ luminal A human breast cancer cells were obtained from
the American Type Culture Collection (Rockville, MD), maintained in RPMI-1640 media
supplemented with 10% fetal bovine serum (FBS) and 100 U/mL each of penicillin and
streptomycin. Cells were maintained at 37°C, 5% carbon dioxide, and 95% humidity. All
media and supplements were obtained from Hyclone (Logan, UT). Human oncostatin M
(OSM) (Peprotech, Rocky Hill, NJ), was added at 25 ng/mL.
Immunofluorescence Staining and Microscopy
2.5 x 105 cells were plated onto glass coverslips (Thermo Fisher Scientific). After
24 hours, cells were treated with or without OSM for 5 days. After experimental
treatment, cells were rinsed once with PBS and then fixed in ice-cold methanol for 20
minutes. Cells were rinsed 3 times with PBS for 10 minutes. Cells were blocked in 1X
PBS/1% BSA/0.5%Triton X-100 (PBSAT) for 30 minutes and then incubated in PBSAT
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overnight containing the primary antibodies for human E-cadherin (1:200, Abcam,
Cambridge, UK), Alpha catenin (1:200; Abcam, Cambridge, UK), or Phalloidin 568 nm
for actin (1:200, Thermo Fisher Scientific, Waltham, MA). Cells were washed 3 times in
PBS and incubated with PBSAT containing goat anti-mouse Alexa Flour 488 (1:1000)
and donkey anti-rabbit Alexa Flour 546 (1:500; Molecular Probes, Invitrogen, Carlsbad,
CA) secondary antibodies for 2 hours. Cells were washed 3 times in PBS and mounted
using Prolong Gold DAPI (Molecular Probes). Stains were visualized and confocal
microscopy images were collected (Biomolecular Research Center, Boise, ID) using a
Zeiss LSM 510 Meta system combined with the Zeiss Axiovert Observer Z1 inverted
microscope and ZEN 2009 imaging software (Carl Zeiss, Inc., Thornwood, NY).
qRT-PCR
Total RNA was collected using RNA STAT-60TM and isolated per the
manufacture’s protocol (Tel-Test; Friendswood, TX). cDNA was synthesized according
to the manufacture’s protocol (High Capacity cDNA Reverse Transcription Kit, Applied
Biostems, In/Life Technologies). A LightCycler 96 (Roche Diagnostic Corporation,
Indianapolis, IN) with settings of preincubation 1 cycle, 2 step amplification 45 cycles,
and high resolution melting 1 cycle; all steps were set at 95° C for 120 seconds.
Western Blot Analysis
For whole cell lysates, 5 x 104 cells were seeded into 24-well plates (Thermo
Fischer Scientific, Rockford, IL), unless otherwise stated. At the end of the experiment,
plates were rinsed with ice-cold PBS, then placed on ice with 125 L of RIPA buffer
(Thermo Fischer Scientific) supplemented with 1:100 dilution of Sigma Protease
Inhibitor Cocktail and 1:1000 phenylmethylsulfonyl fluoride (PMSF) (Sigma, St. Louis,
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MO) for 15 minutes, mixing every 5 minutes. Plates were scraped and the contents
transferred to an Eppendorf tube. Tubes were then centrifuged at 14,000 rpm for 20
minutes.
Lysates were electrophorated on a 7.5-10% SDS-PAGE and transferred to a
nitrocellulose membrane. Immunoblot analysis was performed using primary antibodies
for human E-cadherin (1:2000), β-actin (1:5000), -catenin (1:2500) (Cell Signaling
Secondary, Danvers, MA. CD44 (1:5000) (kindly provided by Dr. Knudson). Antibodies
were HRP-conjugated donkey anti-rabbit (1:5000).
Flow Cytometry
A FACSCaliburTM flow cytometer (BD Biosciences, San Jose, CA) was used to
observe populations of BCSCs present within a heterogeneous population of tumor cells.
Breast tumor cells were treated with OSM (25 ng/mL) for 72 hours before performing
flow cytometry with antibodies (BD Biosciences, San Jose, CA) to CD44 (1:5 FACS
buffer), CD24 (1:5 FACS buffer), FITC (1:50 FACS buffer), and PE (1:50 FACS buffer)
after blocking cells for 10 minutes with 1% BSA. Antibodies bound to their appropriate
proteins for 30 minutes on ice in the dark. Following incubation, cells were washed 3x
with FACS buffer (10% FBS, 0.1% sodium azide in PBS). Software analysis was
performed using BD FACSCalibur software (CellQuest Pro, version 6.0).
shRNA and Chemical Inhibitors
Gene knockdown of CD44 and a non-targeting control sequence were created
using shERWOOD shRNA lentiviral constructs (Transomic Technologies, Huntsville,
AL). Viral transduction of MDA-MB-231 luc and MCF-7 luc cells was performed
according to manufacturer’s protocol. Puromycin was used for initial selection followed
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by fluorescence microscopy to isolate transduced cell population; CD44 expression was
confirmed by western blot analysis.
A MMP inhibitor (GM6001; Santa Cruz Biotechnology), was added to the cell
growth media (10 nM) 2 days before cytokine treatment in serum-free media; followed
by the addition of complete media and OSM for 2 more days.
Detachment Assay
A detachment assay was used to compare relative tumor cell detachment in the
presence or absence of recombinant OSM (25 ng/mL). Cells were plated at 10,000 cells
per well in a 24-well plate and allowed to attach overnight. Once plated, cells were
placed in 1% FBS RPMI media for 4 hours without treatment. After a 4-hour incubation,
cells were then treated with or without OSM in 1% media for the allotted time (1, 3, 5, or
7 days). To assess detached cells, media was collected and centrifuged. The pellets were
resuspended in equal parts of RPMI media and Trypan Blue. Detached cells were then
counted. Cells stained with Trypan blue were excluded from the counts. Proliferation was
also measured, by trypsinizing adherent cells, pelleting cells, resuspending pellets in
equal parts of RPMI media and Trypan blue, and counting cells using a hemocytometer.
Detachment was measured by comparing the number of proliferating cells and detached
cells in the presence or absence of OSM, and fold detachment was calculated.
Scratch Assay
A wound healing assay was used to measure mobility of breast cancer cell with or
without OSM treatment. MCF-7 luc and MDA-MB-231 luc-shCD44 and shNTC control
cells were plated at 200,000 cells per well in a 6-well plate with 10% FBS RPMI media.
Once cells were 80-85% confluent, a scratch was made with a sterile p1000 micropipette
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tip. Wells were washed with PBS followed by the addition of 10% FBS RPMI media
each well, with or without OSM (25 ng/mL). Photomicrographs were taken at 72 hours.
The area of each scratch was measured using ImageJ and the fold-migration was assessed
by comparing day zero scratch area to day three scratch area.
Results
OSM induces EMT and a CD44+/CD24-/low breast cancer stem cell-like phenotype
Estrogen receptor-positive (ER+) breast cancer cells, which are phenotypically
epithelial in nature, undergo an EMT in response to metastatic inducers such as TGF
and OSM (102, 103). Here, our studies showed that ER+ MCF-7 and MCF-7 luc
(luciferase expressing) human breast cancer cells treated with OSM (25 ng/mL)
underwent an EMT over a 3-day period, as displayed by a change in morphology where
individual cells broke away from the initial colony and subsequently took on a more
spindle-like mesenchymal appearance (Fig. 1A and Suppl. Fig. 1). Furthermore,
immunofluorescence microscopy of MCF-7 luc cells demonstrated an OSM-induced
decrease and redistribution of E-cadherin expression (Fig. 1A).
Previous studies have shown that developmental transcription factors such as Slug
and Snail are responsible for repressing the expression of proteins associated with an
epithelial phenotype such as E-cadherin (104). ER+ MCF-7 breast cancer cells treated
with OSM (25 ng/mL) for one hour demonstrated an upregulation of both Slug (p < 0.05)
and Snail by qRT-PCR (Fig. 1B). OSM treatment (25 ng/mL) of MCF-7 breast cancer
cells also resulted in decreased expression of the cell-cell adhesion proteins E-cadherin
and -catenin over time, as measured by western blot analysis (Fig. 1C). These results
demonstrated that OSM was able to initiate an EMT in ER+ breast cancer cells by
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upregulating transcription factors associated with EMT, down regulating the expression
of cell-cell adhesion proteins, and promoting a change in cell morphology from an
epithelial to a mesenchymal phenotype.
Another common feature associated with tumor progression and overall
metastatic burden is an increase in CD44+/CD24low/- breast cancer stem cells (BCSCs)
within a heterogeneous tumor cell population (105). CD44+/CD24low/- cells have been
shown to possess features associated with developmental stem cells as well as controlled
cell division and a presence at the leading edge of a tumor (106). Treatment with OSM
(25 ng/mL) for 72 hours increased the CD44+/CD24low/- BCSC population in ER+ MCF-7
cells from less than 1% to over 1.5% (Fig. 1D) and in T47D cells from 1% to over 4%
(Fig.1E). In untreated ER-negative (ER-) MDA-MB-231 luc cells, the CD44+/CD24low/BCSC cell population was so high (almost 90%) that OSM was unable to induce a BCSC
phenotype (data not shown). Taken together, OSM induced both an EMT and a
CD44+/CD24low/- population of BCSCs in ER+ breast cancer cells, confirming previous
results that OSM drives breast cancer metastatic potential.
OSM Induces Both CD44 Expression and Cleavage
Next, we decided to investigate whether OSM was able to induce CD44s and
variant CD44 protein expression (Fig. 2). Our studies showed that treatment of ER+
MCF-7 cells with OSM (25ng/mL) for 24, 48, and 72 hours resulted in an increase in the
expression of CD44s as well as high molecular weight (MW) CD44 isoforms, as
measured by western blot analysis of whole cell lysates using an antibody specific to the
cytoplasmic fragment of CD44 (Fig. 2A). Additionally, the expression of OSM-induced
CD44s and high MW isoforms were most prevalent at 48 and 72 hours in ER+ T47D
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cells (Fig. 2B). CD44s expression in the more aggressive ER- MDA-MB-231 cells
showed a high basal level, which did not change in the presence of OSM during the same
time period (Fig. 2C). Furthermore, OSM treatment did not alter high MW protein
expression in MDA-MB-231 cells. To support our finding that OSM induced CD44s and
variant CD44 protein expression in ER+ breast cancer cells, we investigated OSMinduced CD44 mRNA levels by qRT-PCR. While a non-significant increase in OSMinduced CD44s expression was observed at 8 hours in MCF-7 cells (Suppl. Fig. 2A),
OSM did not significantly induce the mRNA levels of CD44 variants (v2 through v10)
(Suppl. Fig. 2B). Together, these studies suggest that while OSM does not induce CD44
mRNA expression, it does result in increased levels of CD44s and variant proteins.
Proteolytic cleavage of CD44 by MMPs right outside the membrane and by secretase within the cell membrane produce low molecular CD44 fragments (107, 108).
Our studies demonstrated that OSM treatment of ER+ MCF-7 and T47D cells resulted in
an increase in CD44 cleavage products (~35 kDa and below) (Fig. 2A and B), not seen in
ER- MDA-MB-231 cells (Fig. 2C). Our lab has previously shown that OSM induces
MMP activity in breast tumor cells, such as MMP-9 and MMP-2 (37). Inhibiting MMP
activity using a global MMP inhibitor (GM6001) for 48 hours in ER+ T47D cells
decreased the amount of OSM-induced CD44 cleavage (Suppl. Fig. 3A and B). To
summarize, in ER+ breast cancer cells OSM promoted an increase in CD44s as well as
variant protein levels and induced proteolytic cleavage of CD44, presumably through
OSM-induced MMP activity.
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OSM-Induced EMT is Independent of CD44
To explore the relationship between OSM-driven EMT and OSM-upregulation of
CD44 expression, we established stable breast cancer cell lines with CD44 knockdown
expression using shCD44 lentiviral transduction (Fig. 3A and B). ER+ MCF-7 lucshCD44 cells showed a 80% reduction in CD44s expression by western blot analysis
compared to control shNTC (non-targeting control) cells (Fig. 3A and B), while MDAMB-231 luc-shCD44 cells showed an 85% reduction in CD44s (Fig. 3A and B). MCF-7
luc-shCD44 and control shNTC cells were treated with OSM (25 ng/mL) for 1 hour and
qRT-PCR was performed for evaluate the EMT-driving transcription factors Slug and
Snail. As expected, OSM treatment increased both Slug and Snail over 1.5-fold compared
to untreated MCF-7 luc-shNTC (control) and MCF-7 luc-shCD44 (knockdown) cells
(Fig. 3C, 3D). However, OSM treatment of knockdown MCF-7 luc-shCD44 cells
resulted in no significant change in Slug expression compared to control shNTC cells,
suggesting that CD44 is not involved in the upregulation of Slug by OSM (Fig. 3C).
Interestingly, CD44 knockdown resulted in a significant increase in OSM-induced Snail
expression compared to control shNTC cells, suggesting that the absence of CD44
increased OSM-induced Snail (Fig. 3D).
In the presence of OSM (25 ng/mL) for 72 hours, shNTC and shCD44 cells both
showed a reduction in the cell-cell adhesion protein, E-cadherin by immunofluorescence
(Fig. 3E). Interestingly, we did observe that both untreated and OSM-treated MCF-7 lucshCD44 cells appeared to form much tighter colonies than control MCF-7 luc-NTC
counterpart cells (Fig. 3E) Photomicrographs of MCF-7 luc-shCD44 and shNTC cells
treated with OSM for 72 hours were also taken to observe the phenotypic EMT process
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(Fig. 3F). A similar finding was seen, as MCF-7 luc-shCD44 cells appeared to form
much tighter colonies than control MCF-7 luc-NTC cells. Taken together, these results
suggested that OSM-induced EMT took place independently of CD44 in ER+ MCF-7 luc
cells.
OSM-Induced Tumor Cell Detachment is Dependent on CD44
Our lab has previously shown that OSM induces tumor cell detachment,
particularly in ER+ breast cancer cells (37). MCF-7 luc-shCD44 and MDA-MB-231 lucshCD44 cells were treated with OSM (25 ng/mL), and fold-detachment was measured
over a 5-day period (Fig. 4). OSM induced a 1.8- to 3-fold increase in cell detachment in
ER+ MCF-7 luc-shNTC cells compared to untreated control cells (Fig. 4A; left). When
MCF-7 luc-shCD44 cells were treated with OSM, no significant increase in tumor cell
detachment was measured at days 1, 3, and 5 (Fig. 4A; right). Furthermore, a significant
decrease in cell detachment was seen between OSM-treated control and MCF-7 lucshCD44 cells at days 1 and 5 (Fig. 4), suggesting that knockdown of CD44 eliminated or
delayed the ability of OSM to induce ER+ MCF-7 breast tumor cell detachment. The
more aggressive ER- MDA-MB-231 luc-shNTC control cells did not detach in the
presence or absence of OSM (Fig. 4B; left). Interestingly, MDA-MB-231 luc-shCD44
cells treated with OSM for 5 days showed a 6-fold increase in tumor cell detachment
compared to control cells, similar to MCF-7 luc-shNTC cells (Fig. 4B). Therefore, it
appears that MDA-MB-231 luc-shCD44 cells reverted from aggressive and basically
OSM-unresponsive cells to less aggressive cells that responded to OSM when CD44
expression was reduced. Together, these results suggested that OSM-induced ER+ MCF7 tumor cell detachment is dependent on CD44 expression.
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OSM-Induced Tumor Cell Migration is Dependent on CD44
Tumor cells must become motile to undergo invasion and metastasis. Therefore,
wound healing assays were performed using ER+ MCF-7 luc-shCD44 and MDA-MB231 luc-shCD44 cells to quantitate tumor cell migration. MCF-7 luc-shNTC cells treated
with OSM (25 ng/mL) for 3 days demonstrated a slight 1.5-fold increase in migration
compared to untreated cells (Fig. 5A), Importantly, MCF-7 luc-shCD44 cells migrated to
a significantly less extent when compared to shNTC control cells in the presence of OSM
(Fig. 5A). When treated with OSM for 3 days, the ER- MDA-MB-231 luc-shCD44 cells
showed a nearly 2.5-fold reduction in the number of migrating cells compared to MDAMB-231 luc-shNTC cells (Fig. 5B). This striking difference demonstrates an importance
for CD44 in OSM-induced ER- tumor cell migration. In conclusion, our findings suggest
that OSM-induced CD44 appears to be important in tumor cell detachment and
migration, both necessary for breast cancer cells undergoing metastasis.
Discussion
In this study, we show that OSM induces a breast cancer cell EMT that is not
dependent on the presence of CD44. Rather, CD44 is necessary for tumor cell
detachment and migration regulated by OSM. These results are significant if we are to
understand the overall process of how OSM contributes to breast cancer metastatic
potential.
Our findings here support previously published data demonstrating that OSM
induces an EMT in breast cancer cells (109) and increases a BCSC-like phenotype (110).
In this study, we show for the first time that OSM induces ER+ breast cancer cell CD44
protein expression, including CD44s and variant proteins. Other cytokines/growth factors
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such as TGF- have also been shown to be strong inducers of CD44 expression (100,
111). While it was our expectation that OSM treatment would lead to an induction in the
expression of cancer-related variants such as CD44v6 (112), this was not the case. Our
western blot data demonstrated that the addition of OSM resulted in an increase in the
expression of variant proteins already present before treatment. In TNBC cells, such as
MDA-MB-231 luc cells, OSM did not induce CD44 expression, as basal CD44s levels
were already extremely high. Expression of CD44 variant proteins was not observed in
MDA-MB-231 luc cells with or without OSM treatment.
CD44 protein is capable of undergoing two sequential cleavages by enzymes that
include MMPs and -secretase (107, 113). Our lab and others have previously shown that
OSM induces the expression of a number of MMPs including MMP-2 and MMP-9 (114,
115). Our studies using the non-specific MMP inhibitor GM6001 suggest that OSMinduced CD44 cleavage may be dependent on MMPs. OSM did not induce the expression
of -secretase, nor did a -secretase inhibitor (DAPT) block OSM-induced CD44
cleavage in MCF-7 cells (data not shown). Together, this data suggests that OSM’s
ability to cleave CD44 is limited to MMP activity.
The connection between OSM-induced EMT and CD44 expression was examined
using a MCF-7 luc cell line with knockdown expression of CD44. Reduced CD44
expression did not prevent an EMT in ER+ MCF-7 cells, though untreated MCF-7 lucshCD44 cells grew in much tighter colonies than control cells. Furthermore, treatment of
MCF-7 luc-shCD44 cells with OSM resulted in small clumps of rounded, epithelial-like
cells instead of the classic EMT seen in OSM-treated control cells. These results suggest
that with CD44 knockdown expression, MCF-7 cells display tighter cell-cell adhesion.
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While our studies indicate that CD44 is not directly involved in breast cancer cell EMT,
previous studies have reported a correlation between an increase in CD44 expression and
EMT (45, 116).
Metastatic events such as cellular detachment and migration have often been
thought to be early steps in the metastatic cascade. The connection between OSMinduced cell detachment and migration and CD44 expression was examined using MCF-7
luc and MDA-MB-231 luc cell lines with knockdown expression of CD44. OSM-induced
migration was more prominent in TNBC MDA-MB-231 luc cells than in ER+ MCF-7 luc
cells, though CD44 knockdown reduced OSM-induced migration in both cell types. OSM
promoted ER+ MCF-7 luc cell detachment, similar to our previously published work on
ER+ T47D cells (37). Our studies here show that CD44 expression is necessary for the
increase in cell detachment promoted by OSM. While aggressive cells like MDA-MB231 luc cells do not detach in the presence of OSM, knockdown of CD44 expression
promoted OSM-induced detachment. This interesting finding suggests that loss of CD44
may make MDA-MB-231 cells more responsive to OSM. Taken together, our findings
demonstrate that CD44 contributes to OSM-induced migration and detachment
independently of OSM-induced EMT. These results suggest that regulation of CD44 by
OSM contributes to the breast cancer metastatic cascade.
Conclusion
The studies presented here address a role for CD44 in OSM-induced breast cancer
metastatic potential. The binding of OSM to its receptor leads to the promotion of EMT,
tumor cell migration, and cell detachment (Fig. 6). OSM signaling also increases
expression of the transmembrane protein CD44 and its cleavage, most likely through
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MMP activity. CD44 contributes to OSM-induced migration and detachment, which is
independent of OSM-induced EMT.
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Figure 2.1. OSM induces EMT and a BCSC phenotype in human breast cancer
cells. A. MCF-7 luc human breast cancer cells were treated with OSM (25 ng/mL) for
72 hours. OSM induces an increased mesenchymal phenotype and a slight decrease
and redistribution in E-cadherin expression, as measured by immunofluorescence
using antibodies for E-cadherin (green) and actin (red) (DAPI = blue; 63x
magnification). B. MCF-7 cells were treated with OSM (25 ng/mL) for 1 hour, and
qPCR was performed with primers for the EMT transcription factors Slug (n = 3, +/SEM) and Snail (n = 3, +/- SEM) (Slug *p<.05, paired t test). C. MCF-7 cells were
treated with OSM (25 ng/mL) for 24, 48, and 72 hours, and cell lysates were assessed
by western blot analysis for E-cadherin and α-catenin. D and E. ER+ MCF-7 and
T47D cells were treated with OSM (25 ng/mL) for 72 hours and flow cytometry was
performed for CD44+/CD24-/low. While OSM induces a small non-significant increase
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the CD44+/CD24-/low BCSC population in MCF-7 cells, in T47D cells, OSM induces
the BCSC population 3-fold (+/- SEM for both) (**p<0.005, paired t-test).
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Figure 2.2
OSM induces CD44s (70 – 85 kDa), CD44 isoforms (above 85 kDa), and
cleaved products (below 35 kDa) in ER+ cells but not ER- cells. Cells were treated
with (25 ng/mL) OSM for 24, 48, and 72 hours, and whole cell lysates were collected
for immunoblotting using an anti-CD44 antibody. A. MCF-7 (ER+). B. T47D (ER+).
C. MDA-MB-231 (ER-).
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Figure 2.3. Reduced CD44 expression does not abrogate OSM-induced EMT in
ER+ cells. A. Both MCF-7 luc-shCD44 and MDA-MB-231 luc-shCD44 cells show
knockdown of CD44s protein
30 nm expression compared to non-targeting control (shNTC)
cell lines by western blot analysis. B. Quantification of CD44 knockdown (n = 3, +/SEM, paired t test p < 0.005). C. MCF-7 luc-shNTC and shCD44 cells were treated
with OSM (25 ng/mL) for one hour, and qPCR analysis for Slug and Snail was
performed. Knockdown of CD44 expression did not decrease OSM-induced Slug (C),
but Snail decreased in shNTC compared to shCD44 cells (D) (n=3, +/- SEM, One Way
Anova p < 0.005). E. MCF-7 luc-shNTC and shCD44 cells were treated with OSM (25
ng/mL) for 72 hours, and EMT and E-cadherin was observed via
immunofluorescence (20x magnification scale bar in = 30 nm). F. MCF-7 luc-shNTC
and shCD44 cells were treated with OSM (25 ng/mL) for 72 hours to observe EMT
morphology by phase contrast images (20x magnification scale bar = 200 m).
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Figure 2.4. Reduced CD44 expression decreases OSM-induced tumor cell
detachment in ER+ cells. A. ER+ MCF-7 luc-shNTC and shCD44 cells were treated
with OSM (25 ng/mL) over a 5-day period, and detached cells were counted on days
1, 3, and 5. Data is represented as fold-change (*p<0.05, **p<0.005, ***p<0.001, oneway ANOVA) B. ER- MDA-MB-231 luc-shNTC and shCD44 cells were treated with
OSM (25 ng/mL) over a 5-day period, and detached cells were counted on days 1, 3,
and 5. data is represented as fold change (***p<0.001, one-way ANOVA) (n=3, +/SEM).
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Figure 2.5. Reduced CD44 expression decreases OSM-induced tumor cell
migration in ER- cells to a greater extent than in ER+ cells. A. ER+ MCF-7 lucshNTC and shCD44 cells were treated with OSM (25 ng/mL) for 3 days, and wound
healing was analyzed using ImageJ software. Data was interpreted as fold change
(*p<0.05, one-way ANOVA) (n=3, +/- SEM). B. ER- MDA-MB-231 luc-shNTC and
shCD44 cells were treated with OSM (25 ng/mL) for 3 days, and wound healing was
analyzed using Image J software. Data was interpreted as fold change (***p<0.001,
one-way ANOVA) (n=3, +/- SEM).
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Figure 2.6. Model for OSM-induced migration and detachment. OSM signaling
induces an EMT and upregulates CD44 expression and cleavage in ER+ breast tumor
cells. Once bound to its receptor, OSM induces cells to undergo EMT and subsequent
detachment and migration. OSM signaling also increases expression of the
transmembrane protein CD44 and its cleavage, possibly via MMPs. OSM-induced
CD44 is involved in migration and detachment as well as other downstream events
during the metastatic cascade.

39

Supplemental Figure 2.1. OSM induces an EMT in MCF-7 cells. MCF-7 breast
tumor cells were treated with OSM (25 ng/mL) for 72 hours. OSM induces an
increased mesenchymal phenotype, a redistribution in E-cadherin expression (green,
upper panels, scale bar = 20 nm), and a slight decrease in α-catenin expression (green,
lower panels scale bar = 20 nm), as measured by immunofluorescence (DAPI = blue).
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Supplemental Figure 2.2. OSM has no effect on different CD44 variant mRNA
levels in breast cancer cells. A. MCF-7 cells were treated with OSM (25 ng/mL) for
0.5, 1, 4, and 8 hours followed by RNA collection and qPCR analysis for CD44s (n =
3, +/- SEM). B. MCF-7 cells were treated with OSM (25 ng/mL) for 8 hours followed
by RNA collection and qPCR analysis for different CD44 splice variants. (n = 3, +/SEM).
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Supplemental Figure 2.3. OSM-induced CD44 cleavage is reduced by a general
MMP inhibitor in ER+ breast tumor cells. A. T47D cells were treated with 10 nM of
GM6001 (global MMP inhibitor) for 48 hours prior to the addition of OSM (25
ng/mL) for an additional 48 hours. Whole cell lysates were collected and CD44
western blot analysis was performed to observe cleaved products. OSM induces CD44
in T47D cells after 48 hours; inhibition of MMP activity reduces OSM-induced CD44
cleavage. B. Quantitation of the 15 kDa – 35 kDa bands by ImageJ demonstrate that
GM6001 significantly reduces OSM-induced CD44 cleaved products (n = 3, +/- SEM)
(*p<0.05, unpaired t-test).
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Abstract

The transmembrane cluster of differentiation 44 (CD44) protein has been shown
to be important in breast cancer tumor progression. Here, our studies extend this
knowledge by demonstrating that CD44 is critical for the docking of MDA-MB-231 to
endothelial cells, a crucial step in extravasation and the metastatic cascade. These studies
were performed using a microfluidic chamber lined with human microvascular
endothelial cells (HMECs) over which were flowed MDA-MB-231 luc human breast
cancer cells with knockdown expression of CD44 (MDA-MB-231 luc-shCD44). This
data was supported using an orthotopic MDA-MB-231 luc-shCD44 mouse model of
breast cancer, which showed that reduced CD44 expression resulted in an increased
number of circulating tumor cells (CTCs). Here, we also demonstrated that OSM-induced
CD44+/CD24-/low breast cancer stem cells (BCSCs) injected orthotopically into the
mammary fat pad of mice were capable of initiating tumor formation using just a very
small number of cells (500 cells), thus providing beneficial data to the BCSC theory.
Finally, based on patient OncomineTM data, we show that the complex nature of CD44
does not bode well for its use as a therapeutic intervention, as patients with high levels of
CD44 mRNA expression actually survive longer than patients with low levels of CD44
when OSM receptor expression is low. In conclusion, these studies contribute new
information regarding the role of CD44 in tumor progression and metastasis.
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Introduction

Cluster of differentiation 44 (CD44) is a transmembrane protein that has been
studied across many fields of cancer biology. As a transmembrane protein, its binding to
extracellular hyaluronic acid (HA) occurs through its amino domain (117–120). CD44 is
involved in many aspects of tumor progression and metastasis such as cell survival,
migration, adhesion, signaling, docking, differentiation, and proliferation, and is a key
protein for cytokine signaling (121–123). In order for CD44 to contribute to these events,
it must be cleaved just outside the cell surface by matrix metalloproteinases (MMPs) such
as MMP-9 to release the extracellular domain from the bound portion of CD44 at the
cellular membrane (124, 125). This enables the cell to become migratory after losing
CD44 as an anchoring protein (124, 125). The fragment of CD44 embedded into the
membrane undergoes a second cleavage event by -secretase, which releases the
intracellular domain (ICD) into the cytosol where it can then participate in signal
transduction (99, 113, 126–128). Transcriptional activity following ICD release and
extracellular domain (ECD) cleavage provide many of the key proteins necessary for
tumor metastasis, such as migration and invasion (53, 121). While cleaved, CD44 could
be a potential target during metastasis due to many events the protein is involved in.
One important step in the metastatic cascade is tumor cell extravasation, and
CD44 may play an important role in this process. CD44 and HA are present in many
different cellular environments and on many different cell types, including endothelial
cells (ECs) (129). The binding of CD44 to HA can create a situation where various blood
cell types bind (dock) to ECs by sandwiching HA between each of the cell’s CD44. This
process may also be required for circulating tumor cells (CTCs), as docking requires a
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tumor cell in free flow to come to a stop prior to extravasation, an essential step in the
metastatic process.
Breast tumor masses contain a heterogeneous population of cells including breast
cancer stem cells (BCSCs). BCSCs present a challenge during treatment because they are
able to avoid being targeted by common therapeutics based on their control of selfrenewal genes. Following eradication of a large number of rapidly proliferating primary
tumor cells, the remaining cells possess tumor-initiating properties and the potential for
metastasis and/or recurrence (130). The phenotype widely studied in breast cancer
research that identifies this population of BCSCs is CD44+/CD24-/low.
In this study, we look at the role of CD44 in breast cancer tumor progression.
First, we studied whether CD44 is necessary for breast tumor cell extravasation. Our in
vitro and in vivo findings showed that reduced tumor cell CD44 expression results in
decreased tumor cell docking to endothelial cells and increased CTCs that cannot exit the
bloodstream. Second, we demonstrated that OSM-induced CD44 contributes to an
increased functional population of BCSCs, and we showed that these cells efficiently
develop mammary tumors.
Materials and Methods
Cell Culture
MDA-MB-231 luc cells were stably transduced with lentiviral particles
containing shCD44 shRNA and shNTC (non-targeting control) shRNA. Western blot
analysis was performed to confirm successful knockdown of CD44 (see Chapter 2). Cells
were grown to 90% confluency in a T-75 culture flask. Human microvascular endothelial
cells (HMEC) were grown directly in microfluidic well plates housing hollow fluidic
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channels (Fluxion Biosciences, San Francisco, CA) until the tube displayed an even layer
of cellular attachment. HMEC cells were primed by the addition of TNF- (20 ng/mL) (R
& D Systems, Minneapolis, MN) 24 hours prior to adding MDA-MB-231 luc cells.
Calcein AM cell permeable dye (1/300, Thermo Fisher Scientific) was added 15 minutes
prior to trypsinization of cells.
BioFlux System
BioFlux 200 (Fluxion Biosciences, San Francisco, CA) was used in conjunction
with a microfluidic plate lined with HMEC cells. An EVOS inverted microscope
(Invitrogen™ EVOS™ FL Auto Imaging System) was used to record video and still
frame images of tumor cells as they traveled through a channel while exposed to 0.5, 1.0,
1.5, and 2 dyne/cm2 shear stress over a period of 1 minute per pulse.
Cd44 Knockdown Mouse Model of Breast Cancer
All animal studies were conducted in accordance with the animal component of
research protocol (ACORP) 006-AC15-008 protocol approved by the Institutional
Animal Care and Use Committee (IACUC) at the Boise State University Vivarium,
Boise, ID. In the first in vivo study, 2 x 106 MDA-MB-231-luc-shNTC (control) and
MDA-MB-231-luc-shCD44 were orthotopically injected into the 4th mammary fat pad of
6 to 8-week old female nude mice (n = 3). Tumor size was measured with calipers biweekly once tumors became palpable (after approximately 3 weeks). Bioluminescence
(BLI) of live animals was initiated at 21 days after cell line injection and performed
weekly.
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Bioluminescence in Vivo Imaging of Live Animals
Briefly, mice were injected intra-peritoneal (IP) with 150 mg/kg of D-luciferin
(Caliper Life Sciences) in PBS, anesthetized with 2.5% isoflurane, and imaged. Mice
were imaged using a charge-coupled device camera–based bioluminescence imaging
system (IVIS Spectrum, Caliper Life Sciences; exposure time 1–300 sec, binning 4/8/16,
field of view 23 cm, f/stop 1, emission filter open). Signal was measured and recorded as
total flux (photons/sec). Corresponding grayscale photographs and color luciferase
images were automatically superimposed and analyzed with Living Image software
(Xenogen Biosciences Corporation, Cranbury, NJ).
Flow Cytometry
A BD FACSCaliburTM (San Jose, CA) was used (see Chapter 2) to observe
populations of BCSCs present within a homogenous population. MCF-7 luc cells were
treated with OSM (25 ng/mL) for 72 hours before performing flow cytometry with
antibodies (see Chapter 2). Software analysis was performed using BD FACSCalibur
software: CellQuest Pro, version 6.0 by BD Biosciences.
Cell Sorting
Five T-75 flasks containing MCF-7 luc cells at 80% confluency were treated with
OSM (25 ng/mL) for 72 hours prior to the addition of the following antibodies (BD
Biosciences, San Jose, CA) CD44 (1:5 FACS buffer), CD24 (1:5 FACS buffer), FITC
(1:50 FACS buffer), and PE (1:50 FACS buffer) antibodies after blocking cells for 10
minutes with 1% BSA. Antibodies bound to their appropriate proteins for 30 minutes on
ice in the dark. Following incubation, cells were washed 3x with FACS buffer (10% FBS,
0.1% sodium azide in PBS). Cells were resuspended in FACS buffer before sorting was
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performed. CD44+/CD24low/- cells were collected in a 6 -well plate containing fresh
media. After cell sorting was finished the desired population was placed in an incubator
at 5% CO2, 37 degrees C overnight. Software analysis was performed using BD Influx
software: Spigot, version 6.1.4 by Cytopeia (Seattle, Washington)
Estrogen Pellet Implantation in Mice Receiving Mcf-7 Er+ Cells
For the second in vivo study, estrogen was supplied to athymic nude female mice.
17-estradiol pellets (1.7 mg/90-day release) were obtained from Innovative Research of
America (Sarasota, FL). Animals were placed in a nose cone for anesthesia prior to
surgery. Surgical scissors were used to make a 3-mm opening on the animal’s posterior
neck and a pocket was made by loosening the skin. A single pellet was implanted into the
pocket and gently pressed to secure the pellet. Animals were placed back into their cages
for 48 hours to recover before use in the experiment.
Bcsc Mouse Model of Breast Cancer
MCF-7 luc cells sorted for the CD44+/CD24-/low population and MCF-7 luc
parental cells (control) were suspended in 10 μL of phosphate buffered saline (PBS) and
were injected into the 4th mammary fat pad of 8-week old female nude mice (n=3/group).
Two groups of parental cells were injected; 500 cells/mouse and 2 × 106 cells/animal.
Three groups of cell-sorted CD44+/CD24-/low MCF-7 luc cells were injected (500, 1,000,
and 5,000 BCSCs/animal). Tumor size was measured with calipers bi-weekly once
tumors became palpable (after approximately 3 weeks), and BLI was performed weekly.
Oncomine Data
To explore correlations between patient survival and OSM, OSMR, CD44, and
CD24 status, we attained the Curtis Breast human mRNA microarray dataset from
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Oncomine™ (Compendia Bioscience, Ann Arbor, MI). The constraints used to define the
dataset used were “Invasive Ductal Carcinoma” and a detailed survival status of either
“Alive” or “Dead of Disease.” The resultant dataset was used to calculate quartiles. From
these, the upper quartile (>75th percentile) and lower quartile (<25th percentile) were
selected for comparison in order to clearly depict survival trends that may have been
otherwise muddled by use of all quartile combinations. For co-expression analysis, we
calculated survival curves using patients in the upper and lower quartile of both CD44
and OSMR status being (“high/high”) and the lower quartile of both (“low/low”).
Statistical analyses between survival of two groups was calculated using a log-rank test in
GraphPad Prism 5 software (** = p < 0.01).
Results
Cd44 Is Necessary for Tumor Cell Docking fo Endothelial Cells
Adaptation and survival is necessary for breast tumor cells once they enter the
vascular stream during the metastatic cascade. We wanted to address whether tumor cells
use their transmembrane CD44 to help bind and dock to endothelial cells (ECs) during
extravasation in a fashion similar to how blood cells utilize their CD44 to bind to
hyaluronic acid on ECs prior to their extravasation out of a blood vessel (131). MDAMB-231 luc-shCD44 and MDA-MB-231 luc-shNTC were suspended in standard growth
media, placed in a BioFlux apparatus lined with human microvascular endothelial cells
(HMECs), and subjected to 1 dyne/cm2 of shear stress of force (slightly less than what is
found in large veins) (132). Cellular docking was observed via videos and still-image
microscopy (Fig 1A). Using still images from 5 fluidic events, chambers were flushed
and stationary cells were counted for graphical representation. MDA-MB-231 luc-
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shCD44 cells showed a 5-fold reduction in docking to ECs (Fig. 1B; p = 0.0026)
compared to MDA-MB-231 luc-shNTC control cells. By video, the MDA-MB-231 lucshCD44 cells showed continuous circulation versus control cells, which were much more
likely to dock (video not included). These results suggest that ER- MDA-MB-231 luc
human breast cancer cells require CD44 in order to dock and extravasate during the
metastatic process.
Decreased Cd44 Expression Leads to an Increase in Breast Circulating Tumor Cells
(Ctcs)
Our lab has previously shown that recombinant human OSM (rhOSM) increases
circulating tumor cell (CTC) number and subsequent metastasis in an MDA-MB-231 luc
orthotopic mouse model of breast cancer (manuscript in preparation). To confirm our in
vitro results from Figure 1, and to demonstrate that CD44 is needed for CTCs to dock and
extravasate, and we used the MDA-MB-231 luc-shCD44 orthotopic mouse model of
breast cancer. 2 x 106 MDA-MB-231-luc-shCD44 and shNTC control cells were injected
into the 4th mammary fat pad of female nude mice. Once tumors became palpable
(roughly 5 mm2), the animals received peri-tumoral injections of rhOSM (1 g in PBS)
3x/week for the life of the animal (Fig 2A). BLI images of each animal were recorded
3x/week during the final 8 weeks (12-week total duration of experiment) in order to track
prima tumor growth and metastasis. Blood was collected from each mouse at the
termination of the study, and qPCR was performed to quantify human Alu repeat
sequences (found in human tumor cells but not mouse blood cells), as a measure of
relative CTC count. As expected, injection of OSM resulted in an increase in CTC
number; ~4-fold for MDA-MB-231 luc-shNTC cells and over 2-fold for MDA-MB-231
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luc-shCD44 cells (Fig. 2B). Importantly, knockdown of CD44 expression in the MDAMB-231 cells led to an increase in CTC number (Fig. 2B), suggesting that without CD44,
the tumor cells could not dock and extravasate and remained as CTCs in the blood
stream.
To observe the serological effects of rhOSM and CD44 expression in our mouse
model, blood from each animal was collected and complete blood counts (CBCs) were
analyzed by West Vet (Garden City, ID). As CD44 contributes to the maturation of white
blood cells (WBCs) (133), we investigated neutrophil and lymphocyte values across each
experimental group. We observed a 2- to 3-fold decrease in the number of neutrophils
and mature lymphocytes in the blood of mice injected with MDA-MB-231 luc-shCD44
cells compared to MDA-MB-231 luc-shNTC control cells (Fig. 2C; p = <0.001),
suggesting that decreased CD44 expression resulted in a decrease in these blood cell
counts. OSM had no significant effect on WBC counts (Fig. 2C). In conclusion, a
decrease in CD44 expression, as demonstrated by MDA-MB-231 luc-shCD44 cells,
resulted in an increase in CTC number and a decrease in the number of neutrophils and
lymphocytes. Therefore, CD44 contributes to events in the metastatic cascade through the
promotion of cellular docking as well as through decreasing the number of WBCs that
pose a threat to tumor progression.
A Low Number of Cd44+/Cd24-/Low Breast Cancer Cells (BCSCs) Initiate Tumor
Formation
To investigate the process of tumor initiation, we observed the effects of BCSCs
in vivo. Unlike with ER- MDA-MB-231 cells, ER+ parental MCF-7 luc cells were-sorted
and these BCSCs require the presence of estrogen for tumor cell proliferation. ER+ MCF-
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7 luc cells, cell-sorted for CD44+/CD24-/low expression, were orthotopically injected into
athymic nude mice having received 17-estradiol pellet implantation (Fig. 3A).
Commonly used xenograft mouse models of breast cancer require the orthotopic injection
of a large number of cells (2 x 106) for tumor formation and metastasis, while injection of
BCSCs should require a smaller number of cells (134). To study OSM-induced BCSC
tumor initiation and address the issue of BCSC theory, we performed a pilot study using
2 x 106 and 5,000 parental MCF-7 luc cells orthotopically injected into the 4th mammary
fat pads of athymic mice, and compared tumor initiation to that of the injection of cellsorted MCF-7 luc CD44+/CD24-/low cells (Fig. 3B). Injection of 2 x 106 parental MCF-7
luc cells resulted in 3/3 mice developing tumors (mean 8.5 x 6 mm2) at 5 weeks (Table
1), while 0/3 mice receiving 5,000 cells developed tumors over this same time period
(Table 1). On the other hand, as few as 500 CD44+/CD24-/low BCSCs were capable of
forming a tumor, as 1/3 mice developed a tumor at 5 weeks (Table 1). Primary tumor
initiation precedes all metastatic events and is a first step for tumor progression and
potential downstream metastasis. Here we showed that OSM-induced CD44+/CD24-/low
MCF-7 BCSCs can form tumors in an animal model with the orthotopic injection of as
few as 500 cells.
Cd44 Is Crucial For the Survival Of Human Patients Expressing Low Osmr
To take our metastasis and tumor initiation findings further, we used human
survival data from female patients with breast cancer classified into categories of
relevance. OncomineTM gene expression data was obtained and categorized based on
female breast tumor OSM, OSMR, and CD44 expression status. The survival of patients
with low OSMRexpression (n=172) was investigated and subsequent CD44 expression
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was ranked as high (upper quartile) or low (bottom quartile). Patients with low OSMR
expression and high CD44 expression had a significantly higher percent survival than
patients with low OSMR and low CD44 expression (Fig. 4; p=0.0046). Other categories
that were addressed but were not found significant were: i) OSM low patients who had
either CD44 high or CD44 low (p=0.0586); ii) OSM high patients with either CD44 high
or CD44 low (p=.2719), and iii) OSMR high patients with either CD44 high or CD44
low (p=0.293). The data in Figure 4 suggests that in patients whose breast tumors express
little OSMR, and therefore have a reduced ability to respond to OSM, high CD44
expression may play a role in delaying tumor progression.
Discussion
In these studies, we show that CD44 expression in breast cancer cells is necessary
for tumor cell docking in a simulated vasculature environment, which correlates with
CTCs numbers seen in vivo. Furthermore, OSM-induced CD44+/CD24-/low MCF-7 luc
BCSCs can form tumors when as few as 500 cells were injected into athymic mice.
CD44 has been shown to be critical for memory T cells homing and exiting blood
vessels during the process of fighting infection (135–137). This suggests that a potential
role for CD44 on breast tumor cells could be as a location-specific protein during the
process of extravasation. In our studies, we demonstrated that MDA-MB-231 luc-shNTC
and shCD44 cells behaved quite differently from each other in a orthotopic xenograft
mouse of breast cancer. As expected, rhOSM increased the number of CTCs (manuscript
in preparation) in both mice injected with MDA-MB-231 luc-NTC control and shCD44
cells, but we observed that the number of CTCs from mice injected with MDA-MB-231
luc-shCD44 cells was greater than the number found in mice injected with control cells.
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This data suggests that CD44 is necessary for tumor cells to dock to ECs, which is
essential for the initiation of extravasation. Intravasation appeared to be unaffected by
CD44 levels as both shCD44 and shNTC cells entered the blood and became CTCs.
These important in vivo findings were supported by findings from our microfluidics in
vitro model, which showed that there was a significant decrease in the number of MDAMB-231 luc that docked on ECs when CD44 expression was reduced.
Tumor initiation is necessary for a single cell to proliferate into a primary tumor.
During metastasis, BCSCs are capable of homing to a secondary location as an individual
cell, or a small number of cells that have controlled cell proliferation to establish a
secondary metastatic tumor. Human breast cancer cells display more metastatic behavior
in vivo when introduced into the animal at high cell numbers or using various models that
bypass tumor initiation, such as through intracardiac injection (105). However, our in
vivo model focused on the capacity of tumor formation using CD44+/CD24-/low MCF-7
luc cells orthotopically injected in the murine fat pad and not directly injected into the
circulating blood stream. Here we show as few as 500 BCSCs were capable of tumor
formation even when 5,000 parental cells were not. As this was a pilot study, statistical
analysis could not be performed. Nevertheless, our results suggest the need for our
laboratory to further investigate the role of OSM-induced BCSCs tumor initiation in vivo.
We also compared the expression levels of OSM, OSMR, and CD44 on female
breast cancer patient survival. We found that patients with low levels of OSMR and high
levels of CD44 had a higher survival rate compared to low OSMR and low CD44. As
puzzling as this data seemed, it is suspected that CD44 contributes to both positive and
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negative outcomes during the multi-step process of breast tumor metastasis as shown by
our docking, in vivo, and human patient data.
Conclusion
MDA-MB-231 luc breast tumor cells dock to HMEC cells with CD44 in a fluidic
environment similar to the bloodstream. The absence of CD44 in MDA-MB-231 luc cells
increases the number of CTCs in vivo as they are unable to extravasate during metastasis.
MCF-7 luc cells treated with OSM for 72 hours showed an increase in CD44+/CD24-/low
BCSCs. 500 BCSCs orthotopically injected into mammary fat pads of nude mice
developed tumors compared to parental MCF-7 luc cells that needed large numbers of
cells to develop a palpable tumor.
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Figure 3.1: CD44 increases tumor cell docking in MDA-MB-231 luc cells in an in
vitro model. A. MDA-MB-231 luc-shNTC and shCD44 cells were stained with Calcein
AM for 15 minutes in a cell culture flask in the incubator. Cells were removed from
the flask via trypsin and placed in a conical on ice. 250,000 cells suspended in 0.5 mL
media was slowly added to the BioFlux apparatus where a single layer of HMEC
endothelial was present. Using 1 dyne of shear stress, cells were pumped through the
hollow tube containing endothelial cells. Flow rate was paused followed by a wash
cycle to remove any undocked cells and fluorescent cell counts were performed. B.
MDA-MB-231 luc-shNTC and shCD44 docked cells counted and statistically
analyzed. (n=5, +/- SEM) (p<0.005) p = 0.0026
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Figure 3.2: Orthotopic injection of breast cancer cells with decreased CD44
expression leads to increased CTC numbers and decreased WBC maturation. A.
Nude mice were injected with either MDA-MB-231 luc-shCD44 or shNTC control
cells, and tumor development was observed over a 12-week period. shCD44 and
shNTC groups were split into two groups, and half received rhOSM (1 g) peritumorally 3x/week. B. Following the termination of the experiment, blood was drawn
for each animal for CTC analysis using qPCR for Alu amplification. C. White blood
cell counts for each murine group at the termination of the experiment. A significant
difference of p = <0.001 when comparing shNTC –rhOSM to shCD44 –rhOSM. (n=3,
+/- SEM).
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Figure 3.3: BCSCs promote tumor initiation at low numbers. A. BCSCs and
parental MCF-7 luc cells were collected and orthotopically injected into mammary
fat pads of nude mice to observe tumor initiation. MCF-7 luc cells were treated with
OSM (25 ng/mL) for 72 hours followed by performing flow cytometry analysis B.
OSM increased BCSC phenotype, which was subsequently used for the second animal
experiment and data is shown in Table 1. (n = 3, +/- SEM).
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Figure 3.4: Patients who express low levels of OSMR have a better survival rate if
CD44 levels are high. An OncomineTM microarray data set from invasive ductal
carcinoma patients (n = 172) was sorted to analyze only those who had low levels of
OSMR (n = 86). After isolating OSMR low data, it was then broken into categories of
CD44 low and CD44 high. Statistical analysis between the two groups was performed
by using a log rank test, p = 0.0046.
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Figure 3.5: OSM and CD44 promote metastasis in different ways. OSM binds to
its receptor, signaling downstream events such as EMT, migration, and detachment.
OSM also activates the cleavage of CD44 through MMPs leading to increased
migration and detachment (see Chapter 2). CD44 also leads to breast tumor cell
docking and extravasation.
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Table 1:
CD44+/CD24-/low MCF-7 luc BCSCs are capable of tumor initiation in
vivo. Cells were collected after cell sorting was performed. Following cell sorting,
CD44+/CD24-/low cells were compared to MCF-7 luc parental cells.
CELLS RECEIVED

TUMOR INTITATION

TUMOR AT 5 WEEKS
(mean in mm)

MCF-7 luc
(Parental)
2 x 106

3/3

8.5 x 6

MCF-7 luc
(Parental)
5,000

0/3

0

MCF-7 luc CD44+/CD24(BCSCs)
500

1/3

5x5
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Table 2

NAME
CD44s

Primers

5’
AGTCACAGACCTGCCCAA
TGCCTTT
GACAGCAACCAAGAGGC
AAG
CGTCTTCAAATACCATCTC
AGCA

3’
TTTGCTCCACCTTCTTGACTCC
CATG
TTTGTGTTGTTGTGTGAAGAT
GATT
ATCTTCATCATCAATGCCTGA

CD44v4

AACCACACCACGGGCTTT

CATCCTTGTGGTTGTCTGAAG
TA

CD44v5

ATGTAGACAGAAATGGCA
CCAC

GTGCTTGTAGAATGTGGGGTC

CD44v6

GGCAACTCCTAGTAGTAC
AACG

GTCTTCTCTGGGTGTTTGGC

CD44v7

CTCATACCAGCCATCCAAT
GC

CTTCTTCCTGCTTGATGACCTC

CD44v8

CTCCAGTCATAGTATAAC
GCTTCA

GTTGTCATTGAAAGAGGTCCT
GT

CD44v9

AGCAGAGTAATTCTCAGA
GCTTC

CAGAGTAGAAGTTGTTGGAT
GGT

CD44v10

ATCATTCTGAAGGCTCAA
CTACTT
AGAGACATGACGGTGGTT
TGT

TAAGGAACGATTGACATTAGA
GTTG
GTTTTGCACCCAGAAAGTGTG
A

Snail

GTAAGGGAGGAGGGGAC
AGG

CCCAGGACTCCAAAGCCCTA

-Actin

AGAGCTACGAGCTGCCTG
AC

AGCACTGTGTTGGCGTACAG

CD44v2
CD44v3

Slug
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